CLINICAL ROLE -
Addition of Tremelimumab-actl to Durvalumab-Based Regimen May Broaden Clinical Activity in uHCC, mNSCLC
Both indications for the CTLA-4 inhibitor were approved by the FDA in 2022.
Tebentafusp-tebn Use in HLA-A*02:01–Positive Unresectable or Metastatic Uveal Melanoma
The agent is representative of a new class of drug, ImmTAC.
2 Clarke Drive Cranbury, NJ 08512